VivoSeq
Other

Patent Ductus Arteriosus

9

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Patent ductus arteriosus is an early-stage landscape with 9 programs across 5 companies. The most active players are Validus Pharmaceuticals, GSK, Pfizer. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

40/100

Completion Rate

78/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Validus Pharmaceuticals

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2V

Viatris Specialty LLC

1 program

ApprovedK

Kenvue Brands

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

31

clinical trials

Completed18 · 58%
Unknown status5 · 16%
Terminated3 · 10%
Withdrawn2 · 6%
Recruiting2 · 6%
Active, not recruiting1 · 3%

Clinical Trials

Trial Activity

31 trials

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates
Recruiting·—·N/A·NCT07338370·34 enrolled
Selective Early Medical Treatment of Patent Ductus Arteriosus in Extremely Low Gestational Age Infants: A Pilot RCT
Recruiting·IIWK Health Centre·Phase 3·NCT05011149·100 enrolled
The Effectiveness of Paracetamol Versus Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Neonates
Active, not recruiting·—·N/A·NCT06601114·254 enrolled
Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus
Completed·—·Phase 3·NCT04037514·133 enrolled
IV Acetaminophen and Patent Ductus Arteriosus
Completed·—·N/A·NCT03008876·10 enrolled
Comparative Study of Efficacy and Safety of Oral Ibuprofen and Intravenous Ibuprofen in Closure of Patent Ductus Arteriosus in Very Low Birth Weight Infants
Completed·HHopital La Rabta·Phase 4·NCT00642330·62 enrolled
High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant
Completed·UUniversity of Florence·Phase 2/3·NCT01243996·70 enrolled
Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates
Completed·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT03022253·44 enrolled
Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus
Completed·UUniversity of California, San Francisco·Phase 2·NCT01958320·202 enrolled
Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants
Completed·RRambam Health Care Campus·Phase 2/3·NCT02002741·24 enrolled
Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus
Completed·UUniversity of California, San Francisco·Phase 2·NCT00187447·100 enrolled
Paracetamol in Patent Ductus Arteriosus
Completed·AAziende Chimiche Riunite Angelini Francesco S.p.A·Phase 2·NCT02422966·110 enrolled
Influence of Treatment for Patent Ductus Arteriosus on Cerebral Oxygenation in Preterm Infants
Completed·UUniversity of Ulm·N/A·NCT01428180·35 enrolled
Oral Paracetamol Versus Oral Ibuprofen in Management of Patent Ductus Arteriosus in Preterm Infants: A Randomised Controlled Trial
Completed·ZZekai Tahir Burak Women's Health Research and Education Hospital·Phase 4·NCT01536158·80 enrolled
Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants
Completed·—·Phase 2·NCT05493540·80 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)